Dermata Therapeutics Q2 EPS $(4.18) Misses $(3.79) Estimate
Portfolio Pulse from Benzinga Newsdesk
Dermata Therapeutics (NASDAQ:DRMA) reported a Q2 EPS of $(4.18), missing the analyst consensus estimate of $(3.79) by 10.29%. This represents a 55.77% improvement over the $(9.45) per share loss from the same period last year.
August 07, 2024 | 8:33 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Dermata Therapeutics reported a Q2 EPS of $(4.18), missing the analyst consensus estimate of $(3.79) by 10.29%. Despite the miss, the loss is a significant improvement from the $(9.45) per share loss in the same period last year.
The reported EPS missed analyst expectations, which is generally negative for the stock price. However, the significant improvement from last year's loss may mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100